profit from every $100 of sales.
$0$100
Nektar Therapeutics
$38.44+1.75% today
-35.1% in 1 year
1-year low $35.121-year high $100.35
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Nektar Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $92.1 million in 2022 to $55.2 million in 2025, with -$164 million of profit last year.
SalesProfit
Nektar Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Nektar Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Nektar Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 92 | 90 | 98 | 55 | |
| 70 | 56 | 68 | 55 | |
| -240 | -135 | -130 | -131 | |
| -323 | -243 | -87 | -128 | |
| -368 | -276 | -119 | -164 | |
| -29.55 | -21.75 | -8.70 | -9.73 | |
| 76.5% | 62.5% | 68.8% | 100.0% | |
| -261.0% | -150.0% | -132.0% | -236.8% | |
| -400.0% | -306.3% | -120.9% | -297.1% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 711 | 398 | 304 | 280 |
| Cash | 88 | 35 | 44 | 15 |
| Total debt | 131 | 118 | 103 | 86 |
| Total liabilities | 344 | 267 | 243 | 191 |
| 367 | 131 | 61 | 90 | |
| 12 | 13 | 14 | 17 | |
| -53.3% | -79.7% | -44.1% | -58.2% | |
| -100.4% | -210.8% | -195.9% | -182.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -304 | -193 | -176 | -209 | |
| 6 | 1 | 1 | 0 | |
| -310 | -193 | -177 | -209 | |
| Dividends paid | – | – | – | – |
| – | 0 | 3 | 0 | |
| 57 | 33 | 22 | 13 |
Valuation
- –
- –
- –
- 3.3×
- 23.8×
- –
- –
- -15.9%
- -12.5%
- 0.0%
Profitability
- 100.0%
- -236.8%
- -297.1%
- -217.6%
- -17.2%
- -78.0%
- -87.0%
- -20.7%
- -17.7%
- 220.2%
Growth
- −15.7%
- –
- −17.8%
- –
- +8.4%
Financial health
- –
- 0.14
- 10.9%
- -4.3×
- 10.21
- 10.21
- 0.07
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 959
Bottom 6%of 889
Bottom 6%of 987
What analysts expect
- Average price target
- $132.83
- Range
- $95.00 – $185.00
- 5 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -1.82 | -1.74 | −4.6% |
| Mar 12, 2026 | -1.78 | -2.76 | +35.5% |
| Nov 6, 2025 | -1.85 | -2.85 | +35.1% |
| Aug 7, 2025 | -2.95 | -3.13 | +5.8% |
| May 8, 2025 | -3.30 | -2.70 | −22.2% |
| Mar 12, 2025 | -2.25 | -1.95 | −15.4% |
| Nov 7, 2024 | -0.18 | -0.23 | +21.7% |
| Aug 8, 2024 | -0.25 | -0.21 | −19.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
39No pass
Benjamin Graham
41No pass
Philip Fisher
42No pass
Peter Lynch
29No pass
Joel Greenblatt
2No pass
Charlie Munger
41No pass
Terry Smith
45No pass
Questions about Nektar Therapeutics
Is Nektar Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Nektar Therapeutics AI analysis
What does Nektar Therapeutics do?
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. It is in Biotechnology.
Does Nektar Therapeutics pay a dividend?
No. Nektar Therapeutics does not pay a dividend at the moment.
Is Nektar Therapeutics stock halal?
Yes. Nektar Therapeutics passes our halal screen: its business is permitted and its debt is 7% of its market value, under the 30% limit. How we check
How has Nektar Therapeutics stock done over the past year?
Down 35.1% over the past twelve months, to $38.44. It traded between $35.12 and $100.35 and is 61.7% below its high.
Who are Nektar Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Nektar Therapeutics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.